Rubedo Life Sciences' Senolytic Patent
Patent US11026963B2, granted to Rubedo Life Sciences in 2021, describes chemical compositions for selectively killing senescent cells; which compositions carry enforceable protection and whether any has reached human trials remain unestablished from available data.
Patent US11026963B2 "Senolytic compositions and uses thereof" was granted to Rubedo Life Sciences on June 8, 2021, and remains active. The subject: chemical compounds for the selective elimination of senescent cells.
The patent defines senolytics as agents that preferentially kill senescent cells, often by altering signaling pathways to restore or trigger apoptotic death (programmed cell death). It describes applications across a broad range of senescence-associated diseases and age-related dysfunction, though determining which specific uses carry enforceable protection requires independent-claim analysis.
"Senolytic" appears in the patent title and in the prior-art keyword list; senolytic compounds are the central subject of the invention. The listed inventors are Mark A. Gallop, Julian Klein, and Marco Quarta. The assignee is Rubedo Life Sciences Inc.
The number of described indications is large, which may reflect an attempt to position one mechanism of action across many conditions linked by cellular senescence. This is a hypothesis drawn from the patent's broad language.
The available material does not establish which compositions carry enforceable patent protection (that requires claim analysis), what experimental models tested selectivity, or whether any compound described here has entered human clinical trials.
For context on the intervention class: Senolytics. Full patent text with claims: Patent US11026963B2.
Sources
[1] US11026963B2 - Senolytic compositions and uses thereof
The edge connects a specific active patent to the intervention class it instantiates, with 0.99 confidence grounded in the patent's own title and keywords; it marks the point where a broad longevity concept becomes a proprietary chemical claim, with honest open questions about scope and clinical evidence.